Monimus Capital Management LP purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 137,058 shares of the company's stock, valued at approximately $1,621,000. Roivant Sciences comprises about 1.5% of Monimus Capital Management LP's investment portfolio, making the stock its 25th largest holding.
Other hedge funds have also added to or reduced their stakes in the company. Nordea Investment Management AB lifted its holdings in Roivant Sciences by 22.5% during the 4th quarter. Nordea Investment Management AB now owns 282,834 shares of the company's stock worth $3,306,000 after purchasing an additional 52,031 shares during the last quarter. TOMS Capital Investment Management LP bought a new position in Roivant Sciences during the 3rd quarter worth $46,333,000. Barclays PLC increased its stake in Roivant Sciences by 19.7% during the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after acquiring an additional 75,609 shares during the period. Loomis Sayles & Co. L P increased its stake in Roivant Sciences by 13.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock worth $45,147,000 after acquiring an additional 458,601 shares during the period. Finally, Retirement Systems of Alabama increased its stake in Roivant Sciences by 26.9% during the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after acquiring an additional 112,286 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities analysts have commented on the company. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of "Buy" and an average target price of $18.08.
Check Out Our Latest Research Report on ROIV
Insider Buying and Selling
In related news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the business's stock in a transaction on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares of the company's stock, valued at $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00. Following the transaction, the chief operating officer now directly owns 595,580 shares in the company, valued at $6,843,214.20. The trade was a 14.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,388,170 shares of company stock worth $27,612,299 in the last 90 days. Insiders own 7.90% of the company's stock.
Roivant Sciences Stock Down 1.1 %
Shares of ROIV traded down $0.12 during midday trading on Tuesday, hitting $10.74. The company's stock had a trading volume of 1,204,210 shares, compared to its average volume of 5,488,683. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06. The company's fifty day simple moving average is $10.80 and its two-hundred day simple moving average is $11.49. The stock has a market capitalization of $7.66 billion, a price-to-earnings ratio of -71.50 and a beta of 1.26.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
